Concord Biotech gets SEBI nod for IPO
The IPO is a complete OFS by existing shareholder Helix Investment Holdings
The IPO is a complete OFS by existing shareholder Helix Investment Holdings
QS-21 in blockbuster Shingles vaccine, first vaccine approved for Malaria, promising RSV phase III candidate, and Covid-19 applications.
Ryzneuta is a novel dimeric G- CSF long-acting fusion protein without pegylation. The Biologics License Application (BLA) of Ryzneuta is currently under late-stage review by the US FDA for Chemotherapy-Induced Neutropenia (CIN)
Formulation revenue decreased by 7.6% YoY to Rs. 4,770 crore whereas in Q2 FY23, API business posted a growth of 24.2% YoY with revenue of Rs. 969.4 crore
First and only next-generation protein-based adjuvanted COVID-19 booster approved in Europe
Glenmark’s Sodium Phenylbutyrate Tablets USP, 500 mg, will be distributed in the U.S. by Glenmark Pharmaceuticals USA.
50 lakh coloured Ayushman cards will be distributed to all the beneficiaries across Gujarat, at their doorstep, by National Health Authority empanelled agencies after doing e-KYC of beneficiaries
Transformation to pure-play Innovative Medicines company nears completion
The reliability of their products, evidenced by their inclusion in the WHO emergency use list, has further improved with the addition of Takara Bio's enzymes.
Subscribe To Our Newsletter & Stay Updated